Business Wire

FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors

Breakthrough Therapy Designation is based on the encouraging survival data from the Phase 1 BrainChild-03 trial in children and young adults with diffuse intrinsic pontine glioma (DIPG) BrainChild Bio ...
Business Wire

FDA Grants Regenerative Medicine Advanced Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell Therapy for Incurable Pediatric Brain Tumors

BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical ...